Bli medlem
Bli medlem

Du är här

2017-10-30

DORO AB: Redeye: New ailments revealed in Doro

We had expected a recovery in Q3 and a sales growth of 10 percent but
instead sales fell -2 percent. In North America, Doro has failed to
introduce a 4G phone in time, meaning the weakness in US & Canada
will continue into H2'18. Our EBIT estimates for 2018-2019 drop -40
percent and our base case falls with SEK 13 per share.

Read more in the Research Update by Viktor Westman at:
https://goo.gl/jVvDVG

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment
Banking. https://www.redeye.se/

-----------------------------------------------------------
http://news.cision.com/se/doro-ab/r/redeye--new-ailments-revealed-in-dor...

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.